Various Stages Of Breast Cancer Research Articles

Identification of Gene Expression in Different Stages of Breast Cancer with Machine Learning.

Determining the tumor origin in humans is vital in clinical applications of molecular diagnostics. Metastatic cancer is usually a very aggressive disease with limited diagnostic procedures, despite the fact that many protocols have been evaluated for their effectiveness in prognostication. Research has shown that dysregulation in miRNAs (a class of non-coding, regulatory RNAs) is remarkably involved in oncogenic conditions. This research paper aims to develop a machine learning model that processes an array of miRNAs in 1097 metastatic tissue samples from patients who suffered from various stages of breast cancer. The suggested machine learning model is fed with miRNA quantitative read count data taken from The Cancer Genome Atlas Data Repository. Two main feature-selection techniques have been used, mainly Neighborhood Component Analysis and Minimum Redundancy Maximum Relevance, to identify the most discriminant and relevant miRNAs for their up-regulated and down-regulated states. These miRNAs are then validated as biological identifiers for each of the four cancer stages in breast tumors. Both machine learning algorithms yield performance scores that are significantly higher than the traditional fold-change approach, particularly in earlier stages of cancer, with Neighborhood Component Analysis and Minimum Redundancy Maximum Relevance achieving accuracy scores of up to 0.983 and 0.931, respectively, compared to 0.920 for the FC method. This study underscores the potential of advanced feature-selection methods in enhancing the accuracy of cancer stage identification, paving the way for improved diagnostic and therapeutic strategies in oncology.

Fractional mathematical modeling of breast cancer stages with true data from Saudi Arabia

This research focuses on the development, analysis, and simulation of fractional mathematical models to investigate the transmission dynamics of different phases of breast cancer. The suggested breast cancer model incorporates three often-used fractional operators in epidemiology: Caputo, Caputo–Fabrizio–Caputo, and Atangana–Baleanu–Caputo operators. In this study, the determination of the equilibrium point and its stability analysis is conducted using the Routh–Hurwitz criterion. Additionally, we examine the existence and uniqueness of solutions for the fractional system using Krasnoselskii’s and Banach fixed-point theory. Moreover, the global stability is discussed via the Ulam–Hyres criterion. Furthermore, the fractional models are being verified using reported occurrences of stage IV breast cancer among females in Saudi Arabia from 2004 to 2016. The real data is used to determine the values of the parameters that are fitted using the least squares error-minimizing methodology. Also, residuals and efficiency rates are computed for the integer as well as fractional-order models. Graphical representations are used to illustrate numerical results by examining different choices of fractional order parameters. Then, the dynamic characteristics of various stages of breast cancer are analyzed to demonstrate the impact of fractional order on breast cancer progression and how the rate of chemotherapy influences its behavior. We provide graphical results for a breast cancer model with effective parameters, resulting in fewer future incidences in the population of stages III and IV. Chemotherapy often raises the risk of cardiotoxicity, and our proposed model output reflects this. The goal of this study is to reduce the incidence of cardiotoxicity in chemotherapy patients while also increasing the pace of patient recovery. This research has the potential to significantly improve outcomes for patients and provide information on treatment strategies for breast cancer patients.

Polymorphic variants of the <i>PPP1R21</i> gene associated with the level of sex hormone-binding globulin and the risk of various stages of breast cancer

Aim. To assess the relationship of polymorphic gene variants associated with the level of sex hormone-binding globulin (SHBG) according to genome-wide association studies (GWAS) with the risk of stage I–II and stage III-IV breast cancer. Materials and methods. A comparative genetic analysis was carried out on samples of patients with breast cancer: 254 patients with stages I–II and 91 with stages III–IV, and 1140 females of the control group. The paper considers 4 single nucleotide substitutions associated with the level of circulating SHBG according to GWAS: g.107546375AG PRMT6 (rs17496332), g.27519736TC GCKR (rs780093), g.48419260TC PPP1R21 (rs10454142), g.98364050TA BAIAP2L1 (rs3779195). Results. Differences in the involvement of polymorphic variants of SHBG candidate genes in the development of stages I–II and III–IV breast cancer were revealed. The rs10454142 TC polymorphic variant in the PPP1R21 gene is associated with the risk of stage I–II breast cancer: women with an allelic variant of this locus have a higher risk of early-stage disease (T/T vs. T/C vs. C/C, odds ratio 1.35, 95% confidence interval 1.05-1.75; p=0.021; ppermutat=0.027). Also, an increase in the number of C alleles in the female genotype increased the risk of stage I–II breast cancer by 17–18% per allele. There were no associations of polymorphic variants of SHBG candidate genes with the risk of severe disease (stage III–IV). The single nucleotide substitution rs10454142 TC in the PPP1R21 gene and the single nucleotide polymorphisms strongly linked to it are functionally significant (located in the regions of enhancers and promoters) in the epithelial and myoepithelial cells of the mammary gland and liver, affect the level of genome methylation, and are associated with the level of GTF2A1L gene expression.

Cancer-related post-treatment pain and its impact on treatment satisfaction with medication in women with breast cancer: a cross-sectional study from Palestine.

Pain after therapy is an important clinical problem in patients with breast cancer. Unfortunately, cancer patients have a lower quality of life due to inadequate treatment of posttreatment pain; therefore, improving medication management plans and palliative care has become one of the most important targets of cancer therapy. Therefore, the current study aimed to examine the impact of posttreatment pain on medication satisfaction in patients with various stages of breast cancer in Palestine. A cross-sectional analytical study was conducted et al.-Watani Hospital and An-Najah National University Hospital in the Nablus area. Using the Brief Pain Inventory (BPI), the intensity and interference of pain were evaluated. In addition, patients' satisfaction with cancer management medications was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM). Two hundred fifty-four patients were included in this study. All were women, with a mean ± SD age of 53.1 ± 10.7years. The median score for pain severity was 7.0. Pain in the lower extremities was the most reported location. There was a negative association between the global satisfaction domain and the presence of posttreatment pain (p < 0.001). Furthermore, significant differences and negative correlations were found between global satisfaction and posttreatment pain on the day of the interview (p = 0.001), pain medication (p < 0.001), paracetamol use (p < 0.001), and the presence of side effects (p = 0.003). There were significant negative correlations (p < 0.05) between pain severity and interference with effectiveness (r = -0.258, -0.319, respectively), side effects (r = -0.414, -0.514, respectively), convenience (r = -0.274, -0.307, respectively), and global satisfaction domain scores (r = -0.293, -0.287, respectively). Exposure to chemotherapy was the only significant positive correlation with global satisfaction (p = 0.007). The regression analysis results indicated an independent association between chemotherapy use and a higher global satisfaction score (p = 0.011). Patients with posttreatment pain, side effects, and greater interference of pain with their functioning had lower satisfaction scores. Therefore, better management of their treatment medications, side effects, and pain medications is recommended to enhance their satisfaction and quality of life. Several aspects of palliative care should be organized to improve the patient's satisfaction and quality of life in addition to conducting longitudinal studies to evaluate the pain and satisfaction of different types of cancers.

The intention of utilization and experience toward traditional Chinese medicine among breast cancer patients in the early and late stages: a qualitative study

BackgroundIn Taiwan, breast cancer patients usually take conventional medicine and traditional Chinese medicine simultaneously. The utilization of traditional Chinese medicine among breast cancer patients at various stages has not been examined. This study aims to compare the intention of utilization and experience toward traditional Chinese medicine among early- and late-stage breast cancer patients.MethodThis qualitative research collected data from breast cancer patients through focus groups interview by convenience sampling. Conducted in 2 branches of Taipei City Hospital, a public hospital managed by the Taipei City government. Breast cancer patients > 20 years old and had used TCM for breast cancer therapy for at least 3 months were included in the interview. A semi-structured interview guide was adopted in each focus group interview. In the following data analysis, stages I and II were considered early-stage, and stages III and IV were late-stage. For analyzing the data and reporting the results, we used qualitative content analysis as the approach for data analysis, assisted by NVivo 12. Categories and subcategories were identified through content analysis.ResultsTwelve and seven early- and late-stage breast cancer patients were included in this study, respectively. The side effects were the main intention of utilizing traditional Chinese medicine. Improving side effects and constitution was the main benefit for patients in both stages. Additionally, early-stage breast cancer patients used traditional Chinese medicine to prevent recurrence or metastasis. Late-stage breast cancer patients responded more frequently to the use of traditional Chinese medicine due to the side effects of western medicine. However, some of their symptoms were not fully relieved.ConclusionsBreast cancer staging may influence the intention and utilization of traditional Chinese medicine. Health policymakers should consider the results of this research and the evidence-based illustrations to establish guidelines for integrating traditional Chinese medicine among various stages of breast cancer to improve the outcome and quality of care for cancer patients.

Chemotherapeutic Drugs Used Across Various Stages of Breast Cancer: A Scoping Review

Chemotherapeutic Drugs Used Across Various Stages of Breast Cancer: A Scoping Review

Biomarker Based Detection and Staging of Breast Cancer from Blood Using Raman Spectroscopy and Deep Learning Technique

Breast cancer (BC) or breast neoplasm is causing major menace to the life of women around the world. The significance of early detection and staging of BC has been substantial in diagnosing protocol. This work aims to develop an automated system that combines multivariate data analysis (PCA - principal components analysis) with ensemble recurrent neural network models (stacked OGRU-LSTM) to identify Raman spectral characteristics that can be used as spectral cancer markers for the detection of BC progression and staging. Features of blood plasma from histopathologically diagnosed BC candidates were compared to healthy ones in this study. The same is performed on different leading classification models as the stacked basic RNN, the stacked-RNN-LSTM, and RNN-GRU models. A total of 2,340 Raman spectra generated is evaluated in this study. It is found from the study that stage 3 and stage 2 are structurally identical, but with PCA-Factorial Discriminant Analysis (FDA) they can be distinguished from each other, hence the Raman spectrum pertaining to blood plasma samples of the BC candidates is classified efficiently, yielding potentially high values of specificity and sensitivity for all the BC stages. Comparative classification results show that the stacked OGRU-LSTM model outperforms well for BC detection, and better differentiates various stages of BC by employing the multivariate data analysis technique. The stacked OGRU-LSTM model achieved the highest classification accuracy (97.89 %), Cohen-kappa score (0.928), F1-score (0.957), and the lowermost number of test loss and MSE (0.037), indicating that the model outperforms other baseline classifiers. HIGHLIGHTS The use of Raman spectroscopy in conjunction with deep learning models and multivariate data analysis to diagnose and categorize blood plasma samples as cancerous or noncancerous and staging of breast cancer based on their chemical composition To address the issue of underfitting and overfitting caused by insufficient Raman spectral data, spectral data augmentation techniques were implemented The potential for this technique is used to accurately classify breast cancerous samples and hence reduce the number of unnecessary excisional breast biopsies Stage 3 and stage 2 of breast cancer were found to be structurally identical but can be distinguished from each other using PCA-Factorial Discriminant Analysis with high specificity and sensitivity for all BC stages The stacked OGRU-LSTM model outperformed other baseline classifiers for breast cancer detection and better differentiated various stages of breast cancer by employing multivariate data analysis technique GRAPHICAL ABSTRACT

A study comparing the oncogenic microRNA-21-5p and the CA15-3 characteristics as an effective tumor marker in breast cancer patients from Iraq.

Breast cancer (BC) is a genetic disease in the mammary glands' ducts and lobules, with ductal cancers comprising most of the malignancies. Biomarkers can provide an assessment of cancer diagnosis and prediction. The study aims to compare the expression of serum (miR-21-5p) and CA 15-3 expression in the Iraqi population as more efficient biomarkers, then checked MiRNA-21 main characters as a biomarker comparison with (CA15-3) levels. Circulating serum miRNA-21 expression was measured using (the quantitative Real Time-PCR technique) in 50 patients at various stages of breast cancer compared to 27 healthy controls. Meanwhile, CA 15-3 levels were quantified using electro-chemo luminescence immunoassay (ECLIA) methods. The results show the expression of miRNA-21 and the concentration of CA15-3 increased significantly (p&gt;0.01) in patients as compared to control, but the higher median level of MiRNA-21 than of CA15-3. The ROC curve analysis shows that the accuracy, Overall Model Quality, AUC, sensitivity and specificity of miRNA-21 as a biomarker is much higher than the CA 15-3. In conclusion, miRNA-21 may fill the gap that CA 15-3 still lacks in detecting breast cancer at an early stage. Keywords: Breast cancer, microRNA-21, CA15-3, gene expression, RT-q PCR

The content of cytokines in the blood of patients with various stages of breast cancer

Background. Cytokine homeostasis is an important factor characterizing the general condition and adaptive capabilities of the body of patients with malignant neoplasms. However, the role of various growth factors and their significance in the development and enhancement of malignant growth in breast cancer remain poorly understood.&#x0D; Aim. To evaluate the levels of cytokines - tumor necrosis factor , interleukins-4, -6, -8 and -10 in the blood serum of patients with different stages of breast cancer in comparison with healthy volunteers.&#x0D; Material and methods. The study was conducted in 65 patients aged 25 to 67 years (mean age 44.5 [40.056.5] years). Two groups were distinguished: the first with stage 12, the second with stage 34 of breast cancer. The comparison group consisted of 15 apparently healthy women without cancer, aged 29 to 66 years (mean age 51.0 [39.061.0] years). Blood levels of tumor necrosis factor , interleukins-4, -6, -8 and -10 were studied by enzyme immunoassay. The obtained data were processed using the methods of variation statistics, the Statistica 10.0 software package. The significance of differences was assessed by calculating the median and interquartile interval, analysis of variance was performed using the KruskalWallis H-test, and Dan's Q-test was used for multiple comparisons. The critical significance level p for statistical tests was taken equal to 0.05.&#x0D; Results. In the group of patients with stage 12 breast cancer, an increase in the blood levels of all studied cytokines was revealed in comparison with the group of healthy women: interleukin-6 (p=0.00719), interleukin-8 (p=0.00259), tumor necrosis factor (p=0.00014), interleukin-4 (p1=0.0133), interleukin-10 (p1 0.00001). In the group of patients with stage 34 breast cancer, an increase in blood levels was characteristic of all studied cytokines: interleukin-8 (p=0.00009), tumor necrosis factor (p=0.000004), interleukin-4 (p 0.00001), interleukin-10 (p 0.00001), except for interleukin-6 (p=0.15608). The established patterns in changes in the content of cytokines in the blood of patients with breast cancer at different stages of development can serve as the basis for developing approaches to the diagnosis and treatment of the disease.&#x0D; Conclusion. In patients with breast cancer, the levels of tumor necrosis factor , interleukins-4, -6, -8, -10 (p 0.05) are higher than in healthy women.

Breast cancer stage prediction: a computational approach guided by transcriptome analysis.

Breast cancer is the second leading cancer among women in terms of mortality rate. In recent years, its incidence frequency has been continuously rising across the globe. In this context, the new therapeutic strategies to manage the deadly disease attracts tremendous research focus. However, finding new prognostic predictors to refine the selection of therapy for the various stages of breast cancer is an unattempted issue. Aberrant expression of genes at various stages of cancer progression can be studied to identify specific genes that play a critical role in cancer staging. Moreover, while many schemes for subtype prediction in breast cancer have been explored in the literature, stage-wise classification remains a challenge. These observations motivated the proposed two-phased method: stage-specific gene signature selection and stage classification. In the first phase, meta-analysis of gene expression data is conducted to identify stage-wise biomarkers that were then used in the second phase of cancer classification. From the analysis, 118, 12 and 4 genes respectively in stage I, stage II and stage III are determined as potential biomarkers. Pathway enrichment, gene network and literature analysis validate the significance of the identified genes in breast cancer. In this study, machine learning methods were combined with principal component and posterior probability analysis. Such a scheme offers a unique opportunity to build a meaningful model for predicting breast cancer staging. Among the machine learning models compared, Support Vector Machine (SVM) is found to perform the best for the selected datasets with an accuracy of 92.21% during test data evaluation. Perhaps, biomarker identification performed here for stage-specific cancer treatment would be a meaningful step towards predictive medicine. Significantly, the determination of correct cancer stage using the proposed 134 gene signature set can possibly act as potential target for breast cancer therapeutics.

Chinese Medicine Syndrome Differentiation for Early Breast Cancer: A Multicenter Prospective Clinical Study.

BackgroundChinese medicine (CM) syndrome differentiation is one of the fundamental principles that guide the practice of Chinese herbal medicine (CHM). CHM has been widely used among breast cancer patients. Contemporary literature varies in syndrome diagnosis, and there is a need to standardize syndrome differentiation according to the different stages of breast cancer treatment. This multicenter clinical study aims to identify the CM syndromes and the clinical signs and symptoms in women with early breast cancer.MethodsParticipants who met the inclusion and exclusion criteria were interviewed during the five treatment stages: preoperative, postoperative, chemotherapy, radiation therapy, and endocrine therapy. Patient demographic data and CM syndrome (as recorded by the treating CM clinicians in medical records) were gathered. Signs and symptoms were analyzed using descriptive statistics to derive the standardized CM syndromes using hierarchical cluster analysis.ResultsThe analysis included 964 interviews with 620 participants enrolled between April 29, 2020 and May 30, 2021 from eight participating hospitals in China. The two most frequent syndromes recorded in medical records were dual deficiency of qi and blood, and dual deficiency of qi and yin during all but the preoperative stage. The symptoms of lassitude, lack of strength, and insomnia were common in all but the preoperative stage. Cluster analysis identified two clusters in the preoperative stage that most closely resembled the syndrome diagnoses of liver stagnation with congealing phlegm, and dual deficiency of the liver and kidney. Two clusters—dual deficiency of qi and blood, and dual deficiency of qi and yin—were common to multiple treatment stages. The syndrome cluster of spleen and stomach disharmony existed in both the postoperative and chemotherapy stages. Cluster analysis of the radiation therapy stage identified the unique syndrome of yin deficiency with fire toxin, while the endocrine therapy included the syndromes of liver depression and kidney deficiency.ConclusionsThis multicenter clinical study showed consistency between results from cluster analysis and the most common syndromes recorded in the medical records. Findings from this clinical study will be further validated in a Delphi study to standardize CM syndromes for various stages of breast cancer treatment.Clinical Trial Registration www.chictr.org.cn/index.aspx, identifier ChiCTR2000032497.

Geriatrics Breast Cancer: Stage at Presentation and Relationship of Various Factors with Advanced Stage

Objective: To determine the frequency of various stages of breast cancer at presentation and the relationship of various factors with advanced stage in geriatric patients in Pakistan.&#x0D; Study Design: Prospective longitudinal study.&#x0D; Place and Duration of Study: Department of Oncology, Hameed Latif Hospital, Lahore Pakistan, from Feb to Jul 2018.&#x0D; Methodology: A total of 130 geriatric breast cancer patients between the ages of 60-80 years were included. A biopsy report was noted, which was done in the surgical ward and histopathology was done in the institutional pathology department. The researchers evaluated all the reports. In addition, the stage of the breast cancer documented (stage documented by CT scan chest abdomen and pelvis and bone scan. Chest X-ray and ultrasound abdomen and pelvis report were reviewed in case of CT scan report not available) as per American joint committee on Cancer (AJCC) TNM staging system for breast cancer 8th edition.&#x0D; Results: Mean age was 69.10 ± 5.89 years. 106 (81.54%) patients were between 60 to 70 years of age. The mean duration of disease was 7.48 ± 3.87 months. 52 (40.0%) geriatrics patients presented in stage IV followed by stage III, II, I as 48 (37.00%), 30 (23.0%) and 00(0.0%) respectively. The long duration of illness has a significant relationship with advanced disease (pvalue&lt;0.05).&#x0D; Conclusion: Stage IV is the most common stage of breast cancer at presentation in geriatric patients, followed by stages III, II and I, respectively and the long duration of illness has a significant relationship with advanced disease.

Automated online monitoring of lactate and pyruvate in tamoxifen resistant MCF-7 cells using sequential-injection capillary electrophoresis with contactless conductivity detection (SI-CE-C4D) and correlation with MCT1 and MCT4 genes expression

Breast cancer is among the most common cancer types worldwide. The first and second line treatment protocols for various stages of breast cancer in females rely on tamoxifen. Until now, the development of tamoxifen resistance is not entirely understood. In this study, an automated sequential injection capillary electrophoresis with capacitively coupled contactless conductivity detector was developed for online levels monitoring of both lactate and pyruvate from the supernatant media of MCF-7 cells developing tamoxifen resistance. Changes in concentration of the two metabolites were simultaneously monitored from three model cell cultures and two control untreated cells. The electrophoretic separation was performed under reversed electroosmotic flow conditions. The system delivers high sample throughput at low sample consumption of 20 µL per analysis. The method is robust and achieved high sensitivity and resolution. Limits of detection were 8.0 and 17.0 nM and linear ranges were 0.15–5 and 0.01–1 mM with a correlation coefficient of 0.9951 and 0.9963 for lactate and pyruvate, respectively. Inter-run and intra-run accuracy were in the range of 95.37–107.02% with precision (RSD, %) of ≤9.84%. The method was completely validated and the data obtained were in agreement with results achieved using the lactate and pyruvate assay kits. The highly informative generated data revealed a significant increase in lactate and pyruvate production in the three tamoxifen resistant MCF-7 cells models compared to the two control cells starting from 5.8 hours and 6.8 hours culturing times, respectively. The increase in concentrations of both lactate and pyruvate were correlated with an increase in MCT1 and MCT4 genes expression.

Association of 25-hydroxyvitamin D, Cyclooxygenase-2 and Prostaglandin E2 Serum Levels in Breast Cancer Patients

BACKGROUND: Serum levels of 25-hydroxyvitamin D (25(OH)D), prostaglandin E2 (PGE2), and cyclooxygenase 2 (COX2) expression differ between breast cancer stages. Since, previous studies showed mixed results, in this study, we aimed to analyze vitamin D levels related to breast cancer stages and serum levels of COX2 and PGE2 in Indonesia.METHODS: This was a cross sectional study involving 75 breast cancer patients. Subjects were divided into 3 groups, namely operable early stage (K1), locally advanced stage (K2), and advanced stage (K3). Venous blood samples were taken from each subject, then were analyzed for the 25(OH)D, COX2, and PGE2 serum levels by enzyme-linked immunosorbent assay (ELISA) method.RESULTS: There were significant differences in 25(OH)D among groups (p=0.012); between K1 and K2 (p=0.009) and between K1 and K3 (p=0.023). However, there was no significant difference in serum COX2 level (p=0.328). There were significant differences of PGE2 among groups (p=0.002); between K1 and K2 (p=0.036) and between K1 and K3 (p=0.001). Correlation test showed that there were differences between 25(OH)D serum levels and PGE2 serum level (r=0.306, p=0.008) and also between 25(OH)D serum level and breast cancer stage (r=-0.229; p=0.048).CONCLUSION: There were differences in serum Vitamin D and PGE2 levels at various stages of breast cancer. Serum 25(OH)D levels had weak correlation with breast cancer stage and PGE2 serum level. Serum vitamin D level in advanced breast cancer were lower than early stage breast cancer and indicate a poor prognosis.KEYWORDS: breast cancer, 25-hydroxyvitamin D, cyclooxygenase 2, prostaglandin E2

Abstract 2116: Promoter enrichment of subnucleosomes using breast cancer cell-free DNA

Abstract Breast cancer is the leading cancer diagnosis and the second major cause of cancer-related deaths in women worldwide. The use of non-invasive cell-free DNA (cfDNA) to detect and assess cancer dynamics has recently gained traction with a focus on targeted mutation panels. However, mutation panels have to contend with non-tumor origin of mutations like clonal hematopoiesis and the emergence of novel mutations in the tumor. A potential alternative is to harness the epigenomic, or non-genetic, features of cfDNA. In a healthy individual, blood cell turnover is the major contributor to the cfDNA pool. In cancer, tumor DNA adds to the cfDNA pool, which represents the end product of endogenous nucleases acting on accessible genomic DNA. Since genomic DNA is protected by histone proteins, cfDNA maps the chromatin structure of individual cells that turn over. Subnucleosomes (partially formed structures of nucleosomes that are the building blocks of chromatin) are by-products of transcription and thus reflect small protections enriched in active genes. The enrichment of subnucleosomes at promoters correlate with gene expression profiles of cfDNA tissues-of-origin and based on this knowledge, we hypothesized that we could reconstruct the transcriptional profiles of cancer cells by selectively targeting promoter regions. We first extracted cfDNA from 9 healthy female donors and 8 patient donors with various stages of breast cancer (Stage I, n=1; Stage III, n=1; Stage IV, n=4). We used a single-stranded DNA library protocol that robustly captures highly nicked cfDNA, enabling the genome-wide mapping of both nucleosomes and subnucleosomes. We performed targeted capture of promoter-proximal, nucleosome-protected sequences in cfDNA using non-overlapping tiling probes from transcription start sites to 300 bp downstream. After whole-genome sequencing of pooled libraries, we show that 76.4% (n=13/17) of samples exhibited &amp;gt;10X enrichment compared to unenriched samples, and 64.7% (n=11/17) of samples exhibited &amp;gt;100X enrichment. The enriched samples allowed us to profile &amp;gt;10,000 genes, whereas unenriched samples enabled profiling between 100-10,000 genes at an average sequencing depth of 40 million reads. Overall, we obtain higher depth per sequencing read after enrichment resulting in a high-resolution snapshot of promoter-nucleosome dynamics derived by probing only ~0.18% of the genome. We believe that this significant advancement will allow us not only to identify presence of cancer but also detect distinct tumor states. Citation Format: Alexis Zukowski, Amy Han, Peter Kabos, Srinivas Ramachandran. Promoter enrichment of subnucleosomes using breast cancer cell-free DNA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2116.

A Multicentric non-interventional observational study to determine treatment patterns and response of drugs in various stages of breast cancer along with epidemiology

Cancer is a life-threatening disease which causes to lose cohesiveness and orderliness of normal tissue. These malignant cells can spread to any other organ through blood flow or lymphatic flow and develop malignancy over there; this phenomenon is called metastasis. The aim is to focus on treatment pattern and response of drugs in various stages of breast cancer along with epidemiology. It is a non- interventional multicentric observational study. Female patients confirmed with Breast cancer are included in the study. All the relevant data were collected on a patient demographic form after obtaining informed consent from individual patients. In our study, the mean age of presentation in breast cancer patients was 41.35 years. Further it was found that 40.5% (n = 81) majority-female patients with Breast cancer are from Guntur District and 21.5% (n= 43). The majority of women with Breast cancer have hormone receptor expression of ER+/PR+HER2- was found to be 33% (n= 50). In the study on analyzing comorbidities of the study population, it was noted that 28.5% of women were affected with Diabetes mellitus. In our study, it was found that most of the patients with Breast cancer have been most often prescribed with Adriamycin 27.86%. From these observations, we conclude that late menarche may be one of the etiological causes of breast cancer in women, Invasive carcinoma in situ is the most commonly reported breast cancer in the study. Patients have been diagnosed with breast cancer at their stage 3 of progression, which may be the reason for making it mandatory for more than 50% of patients to undergo 6 to 8 cycles of chemotherapy. Coming to the patterns of drug use, ADRIAMYCIN, CYCLOPHOSPHAMIDE and DOCETAXEL are the three most commonly used single drug and combinational drug therapies among the study population.

Prognostic value of pre-treatment routine hematological parameters in breast carcinoma: Advantageous or deleterious?

Introduction: The most common malignancy which endangers the quality of life in females is breast cancer. It is also the major public problem in society and despite advances in treatment strategies, it still leads to high mortality. In all breast cancer patients, the first assessment done before surgery is the complete blood count (CBC). There exists a strong relationship between immune response of the body and clinical staging of breast cancer. This study aimed to determine the most reliable hematological markers for the prognosis of breast cancer, and to evaluate the correlation between hematological parameters and disease staging.&#x0D; Methods: This study was a case control study conducted for a period of 3 years from Jan 2016 to December 2018 in the Department of Pathology (R.L. hospital and Research Center attached to Sri Devaraj Urs medical college, Tamaka, Kolar, Karnataka). The comparison of the hematological parameters was done between the study group (70 cases) and the control group (20 cases). The relation between the hematological parameters and the various stages of breast cancer was analyzed before initiating the treatment.&#x0D; Results: The majority of the breast cancer patients were of stage 2. The hemoglobin concentration, red blood cell (RBC) count, lymphocyte count, and were reduced in the study group, with a significant difference (p &lt; 0.05) when compared to the controls. Hemoglobin concentration, RBC count, hematocrit, white blood cell (WBC) count, and absolute lymphocyte count were inversely proportional to the stage of breast cancer. The absolute count, ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were directly proportional to the progression of disease.&#x0D; Conclusion: Hemoglobin, RBC count, WBC count (including differential count), NLR, and PLR are the key hematological indicators which predict the severity and mortality risk of breast carcinoma.&#x0D;

Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21

Subject and personal particularities of women having various stages of breast cancer

Introduction:The relevance of the research is on the one hand associated with improvement of medical technologies for oncological diseases treatment contributing to increasing the patients’ life expectancy, which leads to an increase of the actual quantity of oncological patients. On the other hand, it is due to worsening of the quality of life of patients having malignant tumors depending both on treatment methods and the patients’ mental and emotional condition.Objective:This paper is aimed at finding psychological personal determinants that create scientific bases to allow using subjective psychological factors alongside with medical practice in working with cancer patients for improving their quality of life.Methods:The leading approach to studying this problem is the systemic and subject-based approach that allows taking an integral view of subject and personal characteristics of oncological patients. Various questionnaires focused on the coping behavior, viability and control were used as psychodiagnostic techniques for assessing the subject and personal characteristics.Results:In the paper, a review of studies is presented that deal with psychological particularities of women having breast cancer, and psychological features women with breast cancer distinguishing them from healthy women are described. As a result of the research conducted, it has been found there are personal and subjective particularities of self-control, subjective control and viability in women having breast cancer distinguishing them from healthy women.Conclusion:The materials of the paper are of practical importance for practicing psychologists who monitor and adjust the treatment process both in terms of oncologists and of psychological support, which gives the opportunity to adjust treatment methods up to the patient’s mental and emotional condition.

Emerging Theranostic Biogenic Silver Nanomaterials for Breast Cancer: A Systematic Review

Breast cancer remains the second common cause of cancer death in United State women in 2018. Consequently, it is of growing need to explore new strategies to treat cancer at various stages of breast cancer. This review discussing the efficacy of biogenic silver nanoparticles (AgNPs) against breast cancer and/or normal cells and its mechanisms of AgNPs toxicity. The research articles were systematically collected through databases including Cochrane, Web of Science, PubMed, Scopus, Science Direct, ProQuest, Google Scholar, and Embase. Significantly, most of the studies were carried out on MCF-7 cancer cell line. Furthermore, the general approach was phyto-fabrication of AgNPs. Specifically, a hefty 71.27% of studies employed plants to bio-fabricate AgNPs. Additionally, fungi with 14.89% of the studies were the second predominant resources conducted for synthesis of AgNPs. Majority of studies bio-fabricated spherical AgNPs with an average diameter of less than 100 nm. Interestingly, the general approach suggested significant toxic effects of biogenic AgNPs with inhibitory concentration of 50% in breast cancer cell lines, while less toxicity was reported in normal cell lines. Regarding the recent advantages in cancer nanomedicine, it is expected that biogenic AgNPs may emerge as potential breast cancer therapeutic agents alone or in combination with FDA-approved anti-cancer drugs in the near future.